The MDM2-p53 Interaction

Molecular Cancer Research

Volumn 1, Issue 14, 2003, Pages 1001-1008

  Moll, Ute M ^a   Petrenko, Oleksi ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEASOME; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

AUTOREGULATION; CARCINOGENICITY; CELL GROWTH; CELL NUCLEUS; CYTOPLASM; DNA DAMAGE; GENE; GENE CONTROL; GENE INTERACTION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GROWTH INHIBITION; HUMAN; MURINE DOUBLE MINUTE 2 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; UBIQUITINATION;

ANIMALS; BINDING SITES; CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

MURINAE;

EID: 0346455771     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
2. Wu, L. and Levine, A. J. Differential regulation of the p21/WAF-1 and MDM2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the MDM2 gene. Mol. Med., 3: 441-451, 1997.
3. Vousden, K. H. and Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2: 594-604, 2002.
4. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell, 11: 577-590, 2003.
5. Chen, J., Wu, X., Lin, J., and Levine, A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol., 16: 2445-2452, 1996.
6. Finlay, C. A. The MDM-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13: 301-306, 1993.
7. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
8. Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet., 13: 235-244, 1987.
9. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. Rescue of embryonic lethality in MDM2-deficient mice by absence of p53. Nature, 378: 206-208, 1995.
10. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. Rescue of early embryonic lethality in MDM2-deficient mice by deletion of p53. Nature, 378: 203-206, 1995.
11. Barak, Y., Juven, T., Haffner, R., and Oren, M. The MDM2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
12. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
13. Picksley, S. M. and Lane, D. P. The p53-MDM2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? BioEssays, 15: 689-690, 1993.
14. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. MDM2 promotes the rapid degradation of p53. Nature, 387: 296-299, 1997.
15. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by MDM2. Nature, 387: 299-303, 1997.
16. Prives, C. and Hall, P. A. The p53 pathway. J. Pathol., 187: 112-126, 1999.
17. Bottger, A., Bottger, V., Sparks, A., Liu, W. L., Howard, S. F., and Lane, D. P. Design of a synthetic MDM2-binding mini protein that activates the p53 response in vivo. Curr. Biol., 7: 860-869, 1997.
18. Kubbutat, M. H. and Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol., 17: 460-468, 1997.
19. Maki, C. G. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem., 274: 16531-16535, 1999.
20. Shirangi, T. R., Zaika, A., and Moll, U. M. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J., 16: 420-422, 2002.
21. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. MDM2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 275: 8945-8951, 2000.
22. Honda, R., Tanaka, H., and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420: 25-27, 1997.
23. Kubbutat, M. H., Ludwig, R. L., Ashcroft, M., and Vousden, K. H. Regulation of MDM2-directed degradation by the C terminus of p53. Mol. Cell. Biol., 18: 5690-5698, 1998.
24. Lai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., Yang, T., Benfield, P. A., Copeland, R. A., and Auger, K. R. Human MDM2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem., 276: 31357-31367, 2001.
25. Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., and Livingston, D. M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science, 300: 342-344, 2003.
26. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2: 405-415, 1998.
27. Ito, A., Lai, C. H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., and Yao, T. P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J., 20: 1331-1340, 2001.
28. Kobet, E., Zeng, X., Zhu, Y., Keller, D., and Lu, H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a temary complex with the two proteins. Proc. Natl. Acad. Sci. USA, 97: 12547-12552, 2000.
29. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274: 948-953, 1996.
30. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362: 857-860, 1993.
31. Bottger, A., Bottger, V., Garcia-Echeverria, C., Chene, P., Hochkeppel, H. K., Sampson, W., Ang, K., Howard, S. F., Picksley, S. M., and Lane, D. P. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol., 269: 744-756, 1997.
32. Bottger, V., Bottger, A., Howard, S. F., Picksley, S. M., Chene, P., Garcia-Echeverria, C., Hochkeppel, H. K., and Lane, D. P. Identification of novel MDM2 binding peptides by phage display. Oncogene, 13: 2141-2147, 1996.
33. Freedman, D. A., Epstein, C. B., Roth, J. C., and Levine, A. J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med., 3: 248-259, 1997.
34. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274: 948-953, 1996.
35. Schon, O., Friedler, A., Bycroft, M., Freund, S. M., and Fersht, A. R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol., 323: 491-501, 2002.
36. Lai, Z., Auger, K. R., Manubay, C. M., and Copeland, R. A. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys., 381: 278-284, 2000.
37. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., and Appella, E. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on MDM2 binding. J. Biol. Chem., 275: 9278-9283, 2000.
38. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53 (1). Cancer Res., 56: 2649-2654, 1996.
39. Lohrum, M. A., Woods, D. B., Ludwig, R. L., Balint, E., and Vousden, K. H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol., 21: 8521-8532, 2001.
40. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer, 3: 102-109, 2003.
41. Wang, W., Takimoto, R., Rastinejad, F., and El-Deiry, W. S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol., 23: 2171-2181, 2003.
42. Duncan, S. J., Cooper, M. A., and Williams, D. H. Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem. Commun. (Camb.), 7: 316-317, 2003.
43. Duncan, S. J., Grushow, S., Williams, D. H., McNicholas, C., Purewal, R., Hajek, M., Gerlitz, M., Martin, S., Wrigley, S. K., and Moore, M. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc., 124: 14503, 2002.
44. Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Muhlhahn, P., Schumacher, R., Hesse, F., Kaluza, B., Voelter, W., Engh, R. A., and Holak, T. A. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry, 40: 336-344, 2001.
45. Freedman, D. A. and Levine, A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol., 18: 7288-7293, 1998.
46. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17: 554-564, 1998.
47. Tao, W. and Levine, A. J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA, 96: 3077-3080, 1999.
48. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J., 18: 1660-1672, 1999.
49. Zhang, Y. and Xiong, Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science, 292: 1910-1915, 2001.
50. Boyd, S. D., Tsai, K. Y., and Jacks, T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol., 2: 563-568, 2000.
51. Geyer, R. K., Yu, Z. K., and Maki, C. G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol., 2: 569-573, 2000.
52. Lain, S., Midgley, C., Sparks, A., Lane, E. B., and Lane, D. P. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to UIA-positive nuclear bodies associated with the PODs. Exp. Cell Res., 248: 457-472, 1999.
53. Smart, P., Lane, E. B., Lane, D. P., Midgley, C., Vojtesek, B., and Lain, S. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene, 18: 7378-7386, 1999.
54. Brooks, P., Fuertes, G., Murray, R. Z., Bose, S., Knecht, E., Rechsteiner, M. C., Hendil, K. B., Tanaka, K., Dyson, J., and Rivett, J. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J., 346 (Pt. 1): 155-161, 2000.1
55. Palmer, A., Rivett, A. J., Thomson, S., Hendil, K. B., Butcher, G. W., Fuertes, G., and Knecht, E. Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol. Biochem. J., 316 (Pt. 2): 401-407, 1996.
56. Palmer, A., Mason, G. G., Paramio, J. M., Knecht, E., and Rivett, A. J. Changes in proteasome localization during the cell cycle. Eur. J. Cell Biol., 64: 163-175, 1994.
57. Reits, E. A., Benham, A. M., Plougastel, B., Neefjes, J., and Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J., 16: 6087-6094, 1997.
58. Yu, Z. K., Geyer, R. K., and Maki, C. G. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene, 19: 5892-5897, 2000.
59. Joseph, T. W., Zaika, A., and Moll, U. M. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during downregulation of the p53 response after multiple types of DNA damage. FASEB J., 17: 1622-1630, 2003.
60. Meek, D. W. Mechanisms of switching on p53: a role for covalent modification? Oncogene, 18: 7666-7675, 1999.
61. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science, 281: 1677-1679, 1998.
62. Chehab, N. H., Malikzay, A., Appel, M., and Halazonetis, T. D. Chk2/ hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev., 14: 278-288, 2000.
63. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA, 96: 14973-14977, 1999.
64. Lai, Z., Auger, K. R., Manubay, C. M., and Copeland, R. A. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys., 381: 278-284, 2000.
65. Alarcon, R., Koumenis, C., Geyer, R. K., Maki, C. G., and Giaccia, A. J. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res., 59: 6046-6051, 1999.
66. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J., The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
67. Rodriguez, M. S., Desterro, J. M., Lain, S., Midgley, C. A., Lane, D. P., and Hay, R. T. SUMO-1 modification activates the transcriptional response of p53. EMBO J., 18: 6455-6461, 1999.
68. Ashcroft, M., Kubbutat, M. H., and Vousden, K. H. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol., 19: 1751-1758, 1999.
69. Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J., and Herrlich, P., DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene, 18: 1723-1732, 1999.
70. de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S. Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., and Lowe, S. W. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev., 12: 2434-2442, 1998.
71. Hay, T. J. and Meek, D. W. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett., 478: 183-186, 2000.
72. Dumaz, N. and Meek, D. W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J., 18: 7002-7010, 1999.
73. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91: 325-334, 1997.
74. Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M. B., Katzir, E., and Oren, M. ATM-dependent phosphorylation of MDM2 on serine 395: role in p53 activation by DNA damage. Genes Dev., 15: 1067-1077, 2001.
75. Fuchs, S. Y., Lee, C. G., Pan, Z. Q., and Ronai, Z. SUMO-1 modification of MDM2 prevents its self-ubiquitination and increases MDM2 ability to ubiquitinate p53. Cell, 110: 531, 2002.
76. Araki, R., Fukumura, R., Fujimori, A., Taya, Y., Shiloh, Y., Kurimasa, A., Burma, S., Li, G. C., Chen, D. J., Sato, K., Hoki, Y., Tatsumi, K., and Abe, M. Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells. Cancer Res., 59: 3543-3546, 1999.
77. Mayo, L. D., Turchi, J. J., and Berberich, S. J. MDM-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res., 57: 5013-5016, 1997.
78. Zhang, T. and Prives, C. Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem., 276: 29702-29710, 2001.
79. Zhu, Y., Mao, X. O., Sun, Y., Xia, Z., and Greenberg, D. A. p38 Mitogen-activated protein kinase mediates hypoxic regulation of MDM2 and p53 in neurons. J. Biol. Chem., 277: 22909-22914, 2002.
80. Mayo, L. D. and Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA, 98: 11598-11603, 2001.
81. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., and Donner, D. B. PTEN protects p53 from MDM2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem., 277: 5484-5489, 2002.
82. Gottlieb, T. M., Leal, J. F., Seger, R., Taya, Y., and Oren, M. Cross-talk between Akt, p53 and MDM2: possible implications for the regulation of apoptosis. Oncogene, 21: 1299-1303, 2002.
83. Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol., 3: 973-982, 2001.
84. Freeman, D. J., Li, A. G., Wei, G., Li, H. H., Kertesz, N., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., Liu, X., and Wu, H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell, 3: 117-130, 2003.
85. Zaika, A., Marchenko, N., and Moll, U. M. Cytoplasmically "sequestered" wild type p53 protein is resistant to MDM2-mediated degradation. J. Biol. Chem., 274: 27474-27480, 1999.
86. Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., and Gu, W. Parc: a cytoplasmic anchor for p53. Cell, 112: 29-40, 2003.
87. Honda, R. and Yasuda, H. Association of p19(ARF) with MDM2 inhibits ubiquitin ligase activity of MDM2 for tumor suppressor p53. EMBO J., 18: 22-27, 1999.
88. Tao, W. and Levine, A. J. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of MDM2. Proc. Natl. Acad. Sci. USA, 96: 6937-6941, 1999.
89. Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., and Bar-Sagi, D. Nucleolar Arf sequesters MDM2 and activates p53. Nat. Cell Biol., 1: 20-26, 1999.
90. Lohrum, M. A., Ashcroft, M., Kubbutat, M. H., and Vousden, K. H. Identification of a cryptic nucleolar-localization signal in MDM2. Nat. Cell Biol., 2: 179-181, 2000.
91. Llanos, S., Clark, P. A., Rowe, J., and Peters, G., Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat. Cell Biol., 3: 445-452, 2001.
92. Sharpless, N. E. and DePinho, R. A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9: 22-30, 1999.
93. Sherr, C. J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol., 2: 731-737, 2001.
94. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell, 91: 649-659, 1997.
95. Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., and Lowe, S. W. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol., 22: 3497-3508, 2002.
96. Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., and McCormick, F. Opposing effects of Ras on p53: transcriptional activation of MDM2 and induction of p19ARF. Cell, 103: 321-330, 2000.
97. Seavey, S. E., Holubar, M., Saucedo, L. J., and Peny, M. E. The E7 oneoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J. Virol., 73: 7590-7598, 1999.
98. Tolbert, D., Lu, X., Yin, C. Tantama, M., and Van Dyke, T. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol. Cell. Biol., 22: 370-377, 2002.
99. Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., and Jochemsen, A. G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J., 15: 5349-5357, 1996.
100. Finch, R. A., Donoviel, D. B., Potter, D., Shi, M., Fan, A., Freed, D. D., Wang, C. Y., Zambrowicz, B. P., Ramirez-Solis, R., Sands, A. T., and Zhang, N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res., 62: 3221-3225, 2002.
101. Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., and Yuan, Z. M. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem., 277: 19251-19254, 2002.
102. de Graaf P., Little, N. A., Ramos, Y. F., Meulmeester, E., Letteboer, S. J., Jochemsen, A. G. Hdmx protein stability is regulated by the ubiquitin ligase activity of MDM2. J. Biol. Chem., 278: 38315-38324, 2003.
103. Pan, Y. and Chen, J. MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol., 23: 5113-5121, 2003.1
104. Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., and Lozano, G. Rescue of embryonic lethality in MDM4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet., 29: 92-95, 2001.
105. Migliorini, D., Denchi, E. L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., and Marine, J. C. MDM4 (MDMx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol., 22: 5527-5538, 2002.
106. Ramos, Y. F., Stad, R., Attema, J., Peltenburg, L. T., van der Eb, A. J., and Jochemsen, A. G. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res., 61: 1839-1842, 2001.
107. Lohrum, M. A., Ludwig, R. L., Kubbutat, M. H., Hanlon, M., and Vousden, K. H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell, 3: 577-587, 2003.
108. Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., and Benchimol, S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell, 112: 779-791, 2003.
109. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., and Gu, W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature, 416: 648-653, 2002.
110. Buschmann, T., Potapova, O., Bar-Shira, A., Ivanov, V. N., Fuchs, S. Y., Henderson, S., Fried, V. A., Minamoto, T., Alarcon-Vargas, D., Pincus, M. R., Gaarde, W. A., Holbrook, N. J., Shiloh, Y., and Ronai, Z. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol., 21: 2743-2754, 2001.
111. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A., and Oren, M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J., 20: 4912-4922, 2001.